Profound Medical Corp. (PROF)

NCM – Real Time Price. Currency in USD

7.14

-0.11 (-1.52%)

At close: May 12, 2026, 4:00 PM EDT

08.05.2026

Profound Medical Q1 Earnings Call Highlights

Profound Medical NASDAQ: PROF reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supported by new clinical data, payer progress and a growing installed base.

08.05.2026

Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript

07.05.2026

Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates

Profound Medical (PROF) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.36 per share a year ago.

07.05.2026

Profound Medical Reports Strong First Quarter 2026 Financial Results

– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the first quarter ended March 31, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

21.04.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

14.04.2026

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.

01.04.2026

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the interventional MRI (“iMRI”) TULSA Procedure™ will be highlighted in several presentations at the 2026 Society of Interventional Radiology (“SIR”) Annual Scientific Meeting, to be held in Toronto, ON, April 11-15.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Profound Medical Reports Strong First Quarter 2026 Financial Results

21.04.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

01.04.2026

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

27.03.2026

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure™ performed in Dallas Medical Center's state-of-the-art MRI suite.

Profound Medical Corp. (PROF)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Profound Medical Corp. (PROF)

Profound Medical Q1 Earnings Call Highlights

Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript

Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates

Profound Medical Reports Strong First Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Videos

No Data

Press releases

Profound Medical Reports Strong First Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

Profound Medical Q1 Earnings Call Highlights

Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript

Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates

Profound Medical Reports Strong First Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Videos

No Data

Press releases

Profound Medical Reports Strong First Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

Search stocks

Profound Medical Corp. (PROF)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Profound Medical Corp. (PROF)

Profound Medical Q1 Earnings Call Highlights

Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript

Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates

Profound Medical Reports Strong First Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Videos

No Data

Press releases

Profound Medical Reports Strong First Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

Profound Medical Q1 Earnings Call Highlights

Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript

Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates

Profound Medical Reports Strong First Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Videos

No Data

Press releases

Profound Medical Reports Strong First Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone